BR0210426A - Metil análogo de sinvastatina para inibição de hmg-coa redutase e processo de obtenção do mesmo - Google Patents

Metil análogo de sinvastatina para inibição de hmg-coa redutase e processo de obtenção do mesmo

Info

Publication number
BR0210426A
BR0210426A BR0210426-1A BR0210426A BR0210426A BR 0210426 A BR0210426 A BR 0210426A BR 0210426 A BR0210426 A BR 0210426A BR 0210426 A BR0210426 A BR 0210426A
Authority
BR
Brazil
Prior art keywords
obtaining
simvastatin
hmg
coa reductase
reductase inhibition
Prior art date
Application number
BR0210426-1A
Other languages
English (en)
Inventor
Kumar Rajesh Thaper
Dileep Madhava Saridi Kumar
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BR0210426A publication Critical patent/BR0210426A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"METIL ANáLOGO DE SINVASTATINA PARA INIBIçãO DE HMG-CoA REDUTASE E PROCESSO DE OBTENçãO DO MESMO". A presente invenção refere-se a um novo análogo metilado da sinvastatina, que possui a capacidade de inibir a síntese do colesterol. O composto da presente invenção é direcionado para o tratamento e a profilaxia da hipercolesterolemia e de várias outras doenças cardíacas. A presente invenção também se refere a um processo para obtenção deste novo composto.
BR0210426-1A 2001-06-13 2002-06-10 Metil análogo de sinvastatina para inibição de hmg-coa redutase e processo de obtenção do mesmo BR0210426A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN659DE2001 2001-06-13
PCT/IB2002/002112 WO2002100323A2 (en) 2001-06-13 2002-06-10 METHYL ANALOGS OF SIMVASTATIN AS NOVEL HMG-CoA REDUCTASE INHIBITORS

Publications (1)

Publication Number Publication Date
BR0210426A true BR0210426A (pt) 2004-08-17

Family

ID=11097071

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210426-1A BR0210426A (pt) 2001-06-13 2002-06-10 Metil análogo de sinvastatina para inibição de hmg-coa redutase e processo de obtenção do mesmo

Country Status (12)

Country Link
US (1) US6541511B1 (pt)
EP (1) EP1404313A4 (pt)
JP (1) JP2005500282A (pt)
CN (1) CN1535145A (pt)
BR (1) BR0210426A (pt)
CA (1) CA2450617A1 (pt)
CZ (1) CZ200450A3 (pt)
EA (1) EA200400034A1 (pt)
PL (1) PL367885A1 (pt)
SK (1) SK242004A3 (pt)
WO (1) WO2002100323A2 (pt)
ZA (1) ZA200400017B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101126084B1 (ko) * 2008-11-04 2012-03-29 한미홀딩스 주식회사 (3ｓ,4ｓ)-4-((ｒ)-2-(벤질옥시)트라이데실)-3-헥실-2-옥세타논의 제조방법 및 이에 사용되는 중간체
CN102086184A (zh) * 2011-03-03 2011-06-08 上海应用技术学院 5位氟取代的4-羟基-3,4,5,6-四氢-2h-吡喃-2-酮类化合物及其制备方法
EP2983711A4 (en) 2013-04-08 2016-11-23 Cytodyn Inc FELLINED ANTIBODIES AND METHODS OF TREATING RETROVIRAL INFECTIONS IN FELINES
ES2524647B1 (es) * 2013-06-06 2015-09-15 Neuron Bio, S.A. Compuestos neuroprotectores, antiinflamatorios y antiepilépticos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137322A (en) 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
ES493726A0 (es) 1979-07-27 1981-06-16 Sankyo Co Un procedimiento para la preparacion de sales y esteres, de monacolina k utiles como agentes antitlipercolesteremicos.
JPS56142236A (en) 1980-04-08 1981-11-06 Sankyo Co Ltd Ml-236a and mb-530a derivative
US4343814A (en) 1980-11-17 1982-08-10 Merck & Co., Inc. Hypocholesterolemic fermentation products
EP0068038B1 (en) 1981-06-29 1985-09-25 Merck & Co. Inc. (+)-(4r,6s)-(e)-6-(2-(4'-fluoro-3,3',5-trimethyl-(1,1'-biphenyl)-2-yl)ethenyl)-3,4,5,6-tetrahydro-4-hydroxy-2h-pyran-2-one, a process for preparing and a pharmaceutical composition containing the same
US4582915A (en) * 1983-10-11 1986-04-15 Merck & Co., Inc. Process for C-methylation of 2-methylbutyrates
US6376683B1 (en) * 2001-06-01 2002-04-23 Council Of Scientific & Industrial Research Process for the preparation of (4R,6S)-4-hydroxy-6-hydroxymethyl-tetrahydropyran-2-one

Also Published As

Publication number Publication date
JP2005500282A (ja) 2005-01-06
ZA200400017B (en) 2004-10-25
WO2002100323A2 (en) 2002-12-19
CA2450617A1 (en) 2002-12-19
WO2002100323A3 (en) 2003-09-18
PL367885A1 (en) 2005-03-07
EP1404313A4 (en) 2006-01-18
US6541511B1 (en) 2003-04-01
CZ200450A3 (cs) 2004-05-12
EA200400034A1 (ru) 2004-06-24
SK242004A3 (en) 2004-06-08
EP1404313A2 (en) 2004-04-07
CN1535145A (zh) 2004-10-06

Similar Documents

Publication Publication Date Title
BR0014075A (pt) Inibidores de quinase como agentes terapêuticos
BR0010555A (pt) Inibidores de neuraminidases
ES2194202T3 (es) Compuestos polimorfos.
BG105559A (en) STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR
BR9915267A (pt) Métodos de tratamento, prevenção ou redução derisco de doença de alzheimer
HUP0104240A2 (hu) Eljárás ateroszklerozis kezelésére egy aP2 inhibítor vagy kombinációja alkalmazásával
BR9916565A (pt) Combinações de inibidores do transporte ácido da bile ileal e derivados do ácido fìbrico para indicações cardiovasculares
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
UY29927A1 (es) Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones
HK1082668A1 (en) Remedies for glomerular diseases
BR0210842A (pt) Processo para a preparação de intermediários úteis na sìntese de derivados de estatina, especialmente derivados do ácido 7-amino 3,5-dihidróxi heptanóico, e intermediários dos mesmos
BRPI0518300A2 (pt) derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia
WO2000048626A3 (en) Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammation associated with pulmonary disease
BR0210266A (pt) Composição farmacêutica que compreende um inibidor de lìpases, processo para preparar essa composição, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
ATE357453T1 (de) Comt-inhibitoren
DE60015508T2 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
BR0210426A (pt) Metil análogo de sinvastatina para inibição de hmg-coa redutase e processo de obtenção do mesmo
BR9813542A (pt) Combinações de estatina-éter carboxialquìlico
SE0101082D0 (sv) Novel use
NO20002370L (no) 2-Aryl-3-aroylbenzo[b]tiofener til behandling av østrogen- deprivasjonssyndrom
BRPI0411245A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de vìrus oncogênicos e para tratamento ou profilaxia de condições ou distúrbios devidos a infecção por hpv
TW200503707A (en) Application of intestinal biliary acid reuptake inhibitors for the prevention and threatment of alzheimer's disease
BR0209776A (pt) Composições de inibidores seletivos de ciclo oxigenase-2 e radiação para inibição ou prevenção de doença cardiovascular
BR0017141A (pt) Processo para produção de simvastatina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]